Publications by Founders

    Preserving Insulin Secretion in Diabetes by Inhibiting VDAC 1 Over expression and Surface Translocation in 𝛃 Cells

    January 08, 2019


    Type 2 diabetes (T2D) develops after years of prediabetes during which high glucose (glucotoxicity) impairs insulin secretion. We report that the ATP-conducting mitochondrial outer membrane voltage-dependent anion channel-1 (VDAC1) is upregulated in islets from T2D and non-diabetic organ donors under glucotoxic conditions. This is caused by a glucotoxicity-induced transcriptional program, triggered during years of prediabetes with suboptimal blood glucose control. 


    Read more >

    Abarceo Pharma AB

    Medeon Science Park, Inkubatorn, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden, 

    reg. no 559139-7160

    © 2018 by Abarceo Pharma AB

    This site was designed with the
    website builder. Create your website today.
    Start Now